Alkem Labs launches affordable antiepileptic drug in India

Mumbai based Alkem Laboratories has announced the launch of Brivasure, an affordable anti-epileptic drug for the treatment of epilepsy in India. Brivasure, Alkem’s antiepileptic drug (AED) is a generic version of the parent molecule. Alkem has launched the drug in the market at price, Brivasure 25mg Rs 79.50/strip, Brivasure 50mg Rs 148.50/strip, Brivasure 75mg Rs 230/strip, Brivasure 100mg Rs 295/strip, post-patent expiry of innovator product, of Brivaracetam as on February 21, 2021. The drug has been approved by the Drugs Controller General of India (DCGI) in the adjunctive management of partial-onset seizure with or without secondary generalisation. The drug has exhibited a faster onset of action, efficacy with a favourable safety profile. With the introduction of Brivaracetam, the company is optimistic about making steady progress and revolutionising epilepsy treatment in India as well as globally.